Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal’s presentation at the Sept. 10, 2026 Cantor Global Healthcare Conference will be webcast live, with a replay posted on its Investor Relations events page.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (MDGL) will participate in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 1:00 p.m. EDT. The company’s presentation will be webcast live and accessible via Madrigal’s Investor Relations Events and Presentations page, with a replay available after the event.
Details
News Market Reaction – MDGL
On Sep 2, the day this news came out, MDGL closed 1.53% above the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Conference Date
- September 10, 2026
- 2026 Cantor Global Healthcare Conference
- Presentation Time
- 1:00 P.M. EDT
- September 10, 2026 conference presentation
Historical Context
-
Employee equity awards were followed by a modest negative price reaction.
-
Appointment of an experienced biopharmaceutical executive was followed by a modest gain.
-
Employee equity awards were followed by a nearly unchanged negative reaction.
-
A conference participation announcement was followed by a negative price reaction.
-
Quarterly results and corporate updates were followed by a sharp negative price reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 1:00 P.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.